{"id":63258,"date":"2026-04-15T22:41:05","date_gmt":"2026-04-15T14:41:05","guid":{"rendered":"https:\/\/flcube.com\/?p=63258"},"modified":"2026-04-15T22:41:06","modified_gmt":"2026-04-15T14:41:06","slug":"chinas-state-council-unveils-comprehensive-drug-pricing-reforms-to-strengthen-market-oriented-mechanisms-and-innovation-incentives","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63258","title":{"rendered":"China&#8217;s State Council Unveils Comprehensive Drug Pricing Reforms to Strengthen Market-Oriented Mechanisms and Innovation Incentives"},"content":{"rendered":"\n<p>The <strong>State Council<\/strong> released the <strong>&#8220;Opinions on Improving the Drug Pricing Mechanism&#8221;<\/strong> this week, introducing sweeping reforms to refine China&#8217;s <strong>market-oriented drug pricing framework<\/strong>, establish clear differentiation between drug innovation tiers, and strengthen the <strong>multi-tiered medical insurance system<\/strong> while expanding payment channels for innovative therapies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-policy-framework-overview\">Policy Framework Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Reform Area<\/th><th>Key Provisions<\/th><\/tr><\/thead><tbody><tr><td><strong>Pricing Mechanism<\/strong><\/td><td>Enhanced market-oriented approach with manufacturer self-assessment system for newly launched drugs<\/td><\/tr><tr><td><strong>Drug Classification<\/strong><\/td><td>Clear differentiation between high-innovative drugs, modified drugs, and generic drugs<\/td><\/tr><tr><td><strong>Procurement Requirements<\/strong><\/td><td>All drugs used by public medical institutions must be procured through provincial-level platforms<\/td><\/tr><tr><td><strong>Markup Policy<\/strong><\/td><td>Zero markup mandated for all drugs (excluding traditional Chinese medicine decoction pieces); extended to TCM formula granules<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-implementation-structure\">Implementation Structure<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-new-drug-pricing-system\">New Drug Pricing System<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Self-Assessment Framework<\/strong>: Manufacturers implement self-assessment for newly launched drugs<\/li>\n\n\n\n<li><strong>Initial Listing<\/strong>: New drugs listed online at initial offering prices<\/li>\n\n\n\n<li><strong>Policy Support<\/strong>: Government guidance provided for appropriate pricing of different drug categories<\/li>\n\n\n\n<li><strong>Dynamic Adjustment<\/strong>: Improved system for ongoing price adjustments based on market conditions<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-procurement-amp-reimbursement-integration\">Procurement &amp; Reimbursement Integration<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Volume-Based Procurement (VBP)<\/strong>: Drugs included in VBP listed at agreed-upon negotiated prices<\/li>\n\n\n\n<li><strong>National Reimbursement Drug List (NRDL)<\/strong>: Negotiated and bidding drugs listed at agreed prices<\/li>\n\n\n\n<li><strong>Other Drugs<\/strong>: Marketing authorization holders determine listing prices per established rules and price comparison frameworks<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-innovation-incentive-measures\">Innovation Incentive Measures<\/h2>\n\n\n\n<p>The policy explicitly aims to support pharmaceutical innovation through multiple mechanisms:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Multi-Party Negotiations<\/strong>: Expanded stakeholder involvement in innovative drug price negotiations<\/li>\n\n\n\n<li><strong>Payment Channel Diversification<\/strong>: Broader reimbursement pathways for innovative therapies<\/li>\n\n\n\n<li><strong>Commercial Insurance Integration<\/strong>: Enhanced role for commercial health insurance in covering innovative drugs<\/li>\n\n\n\n<li><strong>Charitable Initiatives<\/strong>: Leveraging charitable programs to improve patient access<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-real-world-evidence-framework\">Real-World Evidence Framework<\/h2>\n\n\n\n<p>A comprehensive real-world research infrastructure will be established to support evidence-based pricing and reimbursement decisions:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Framework Enhancement<\/strong>: Improved rules, procedures, and standards for real-world drug research<\/li>\n\n\n\n<li><strong>Research Prioritization<\/strong>: Encouragement of real-world studies on NRDL and commercial insurance catalog drugs<\/li>\n\n\n\n<li><strong>Value Assessment<\/strong>: Scientific and objective evaluation of drug value using real-world data<\/li>\n\n\n\n<li><strong>Policy Integration<\/strong>: Real-world evidence to inform dynamic adjustment of medical insurance catalogs and payment standards<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-pharmaceutical-companies\">For Pharmaceutical Companies<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Innovation Premium<\/strong>: Clear differentiation between high-innovative, modified, and generic drugs creates pricing tier structure<\/li>\n\n\n\n<li><strong>Market Access Clarity<\/strong>: Transparent procurement and pricing rules reduce regulatory uncertainty<\/li>\n\n\n\n<li><strong>Reimbursement Opportunities<\/strong>: Multiple payment channels improve commercial prospects for innovative therapies<\/li>\n\n\n\n<li><strong>Evidence Generation<\/strong>: Real-world research requirements create both challenges and opportunities for robust value demonstration<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-healthcare-system\">For Healthcare System<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cost Control<\/strong>: Zero markup policy and centralized procurement maintain affordability<\/li>\n\n\n\n<li><strong>Quality Assurance<\/strong>: Market-oriented mechanisms reward genuine innovation while controlling generic drug costs<\/li>\n\n\n\n<li><strong>Access Improvement<\/strong>: Multi-tiered insurance system expands patient access to innovative therapies<\/li>\n\n\n\n<li><strong>System Efficiency<\/strong>: Dynamic pricing adjustments ensure optimal resource allocation<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-industry-outlook\">Industry Outlook<\/h2>\n\n\n\n<p>This comprehensive reform represents a <strong>maturation of China&#8217;s pharmaceutical policy framework<\/strong>, balancing cost containment objectives with innovation incentives. The explicit recognition of different drug innovation tiers acknowledges that not all new drugs provide equal therapeutic value, creating a more sophisticated pricing environment.<\/p>\n\n\n\n<p>The integration of <strong>real-world evidence<\/strong> into pricing and reimbursement decisions aligns China with international best practices, while the expansion of <strong>commercial insurance roles<\/strong> reflects the government&#8217;s strategy to develop sustainable multi-payer healthcare financing.<\/p>\n\n\n\n<p>For multinational and domestic pharmaceutical companies, the policy creates a more predictable regulatory environment with clear pathways for market access, while maintaining pressure on pricing through competitive procurement mechanisms.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding policy implementation, market dynamics, and regulatory impacts of China&#8217;s drug pricing reforms. Actual outcomes may differ due to risks including implementation timelines, stakeholder adoption rates, competitive responses, and evolving healthcare policy priorities in China&#8217;s rapidly transforming pharmaceutical market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The State Council released the &#8220;Opinions on Improving the Drug Pricing Mechanism&#8221; this week, introducing&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[],"class_list":["post-63258","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China&#039;s State Council Unveils Comprehensive Drug Pricing Reforms to Strengthen Market-Oriented Mechanisms and Innovation Incentives - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The State Council released the &quot;Opinions on Improving the Drug Pricing Mechanism&quot; this week, introducing sweeping reforms to refine China&#039;s market-oriented drug pricing framework, establish clear differentiation between drug innovation tiers, and strengthen the multi-tiered medical insurance system while expanding payment channels for innovative therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63258\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China&#039;s State Council Unveils Comprehensive Drug Pricing Reforms to Strengthen Market-Oriented Mechanisms and Innovation Incentives\" \/>\n<meta property=\"og:description\" content=\"The State Council released the &quot;Opinions on Improving the Drug Pricing Mechanism&quot; this week, introducing sweeping reforms to refine China&#039;s market-oriented drug pricing framework, establish clear differentiation between drug innovation tiers, and strengthen the multi-tiered medical insurance system while expanding payment channels for innovative therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63258\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-15T14:41:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-15T14:41:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63258#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63258\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China&#8217;s State Council Unveils Comprehensive Drug Pricing Reforms to Strengthen Market-Oriented Mechanisms and Innovation Incentives\",\"datePublished\":\"2026-04-15T14:41:05+00:00\",\"dateModified\":\"2026-04-15T14:41:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63258\"},\"wordCount\":605,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63258#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63258\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63258\",\"name\":\"China's State Council Unveils Comprehensive Drug Pricing Reforms to Strengthen Market-Oriented Mechanisms and Innovation Incentives - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-15T14:41:05+00:00\",\"dateModified\":\"2026-04-15T14:41:06+00:00\",\"description\":\"The State Council released the \\\"Opinions on Improving the Drug Pricing Mechanism\\\" this week, introducing sweeping reforms to refine China's market-oriented drug pricing framework, establish clear differentiation between drug innovation tiers, and strengthen the multi-tiered medical insurance system while expanding payment channels for innovative therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63258#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63258\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63258#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China&#8217;s State Council Unveils Comprehensive Drug Pricing Reforms to Strengthen Market-Oriented Mechanisms and Innovation Incentives\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China's State Council Unveils Comprehensive Drug Pricing Reforms to Strengthen Market-Oriented Mechanisms and Innovation Incentives - Insight, China&#039;s Pharmaceutical Industry","description":"The State Council released the \"Opinions on Improving the Drug Pricing Mechanism\" this week, introducing sweeping reforms to refine China's market-oriented drug pricing framework, establish clear differentiation between drug innovation tiers, and strengthen the multi-tiered medical insurance system while expanding payment channels for innovative therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63258","og_locale":"en_US","og_type":"article","og_title":"China's State Council Unveils Comprehensive Drug Pricing Reforms to Strengthen Market-Oriented Mechanisms and Innovation Incentives","og_description":"The State Council released the \"Opinions on Improving the Drug Pricing Mechanism\" this week, introducing sweeping reforms to refine China's market-oriented drug pricing framework, establish clear differentiation between drug innovation tiers, and strengthen the multi-tiered medical insurance system while expanding payment channels for innovative therapies.","og_url":"https:\/\/flcube.com\/?p=63258","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-15T14:41:05+00:00","article_modified_time":"2026-04-15T14:41:06+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63258#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63258"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China&#8217;s State Council Unveils Comprehensive Drug Pricing Reforms to Strengthen Market-Oriented Mechanisms and Innovation Incentives","datePublished":"2026-04-15T14:41:05+00:00","dateModified":"2026-04-15T14:41:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63258"},"wordCount":605,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63258#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63258","url":"https:\/\/flcube.com\/?p=63258","name":"China's State Council Unveils Comprehensive Drug Pricing Reforms to Strengthen Market-Oriented Mechanisms and Innovation Incentives - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-15T14:41:05+00:00","dateModified":"2026-04-15T14:41:06+00:00","description":"The State Council released the \"Opinions on Improving the Drug Pricing Mechanism\" this week, introducing sweeping reforms to refine China's market-oriented drug pricing framework, establish clear differentiation between drug innovation tiers, and strengthen the multi-tiered medical insurance system while expanding payment channels for innovative therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63258#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63258"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63258#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China&#8217;s State Council Unveils Comprehensive Drug Pricing Reforms to Strengthen Market-Oriented Mechanisms and Innovation Incentives"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63258","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63258"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63258\/revisions"}],"predecessor-version":[{"id":63259,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63258\/revisions\/63259"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63258"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63258"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63258"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}